Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Mansoura University
Modality
Small molecule
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Radiation-Induced Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rifaximin (this asset) | Mansoura University | P1/2 | CCC · 48 |
| Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal Rhufab V2 1-Chain), Disulfide With Human-Mouse Monoclonal Rhufab V2 Light Chain | The New York Eye Cancer Center | P4 | BBB |
| Losartan | Massachusetts General Hospital | P2 | B |
| Corpril | Wake Forest University Health Sciences | P2 | B |
| Chlorophyllin Copper Complex Sodium | Tata Memorial Centre | P2 | CCC |
| Ozurdex | Arman Mashayekhi | P2 | CCC |
| Ivonescimab | Zhejiang Cancer Hospital | P2 | CCC |
| [68ga]cbp8 | Massachusetts General Hospital | P2 | CCC |
| Dexasone | Sixth Affiliated Hospital, Sun Yat-sen University | P2 | CCC |
+5 more in the Radiation-Induced Disorder cohort
Other indications for Rifaximin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatic Encephalopathy | — | P4 | BBB · 75 |
| Cirrhosis Of Liver | — | P4 | BBB · 72 |
| Hepatitis C Virus Infection | — | P4 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- Immunoglobulin G1, Anti-(Human Vascular Endothelial Growth Factor) Fab Fragment (Human-Mouse Monoclonal Rhufab V2 1-Chain), Disulfide With Human-Mouse Monoclonal Rhufab V2 Light ChainThe New York Eye Cancer CenterBBB
- LosartanMassachusetts General HospitalB
- CorprilWake Forest University Health SciencesB
- Chlorophyllin Copper Complex SodiumTata Memorial CentreCCC
- OzurdexArman MashayekhiCCC
Citation
Floatz Terminal. Rifaximin in Radiation-Induced Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rifaximin-radiation-induced-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →